Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Combined With S-1 in Resected Cholangiocarcinoma
NCT07561775Phase 2Not yet recruiting
- Start
- Apr 2026
- Primary completion
- Jan 2028
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in cholangiocarcinoma (CCA). Primary endpoint: 1-year Relapse-Free Survival rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT07561775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07561775.